oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Meningococcal serogroup Y emergence in Europe High importance in some European regions in 2012
Novartis Vaccines & Diagnost GmbH, Marburg, Germany..
Univ Hosp Infect Dis Dr Fran Mihaljevic, Zagreb, Croatia..
Inst Publ Hlth, Haemophilus & Meningococcus Reference Lab, Ctr Microbiol, Srbija, Serbia..
Orebro University Hospital.
Show others and affiliations
2014 (English)In: Human Vaccines & Immunotherapeutics, ISSN 2164-5515, E-ISSN 2164-554X, Vol. 10, no 6, 1725-1728 p.Article in journal (Refereed) Published
Abstract [en]

Neisseria meningitidis is differentiated into 12 distinct serogroups, of which A, B, C, W, X, and Y are medically most important and represent an important health problem in different parts of the world. The epidemiology of N. meningitidis is unpredictable over time and across geographic regions. Recent epidemiological surveillance has indicated an increase of serogroup Y invasive meningococcal disease in some parts of Europe as shown in the epidemiological data for 2010 and 2011 from various European countries previously published in this journal. 1,2 Here, data from 33 European countries is reported indicating that the emergence of serogroup Y continued in 2012 in various regions of Europe, especially in Scandinavia, while in Eastern and South-Eastern Europe the importance of serogroup Y remained low.

Place, publisher, year, edition, pages
Landes Bioscience , 2014. Vol. 10, no 6, 1725-1728 p.
Keyword [en]
epidemiology, Europe, invasive meningococcal disease, serogroup Y, meningococcal vaccines, surveillance
National Category
Immunology in the medical area Microbiology in the medical area
Identifiers
URN: urn:nbn:se:oru:diva-56351DOI: 10.4161/hv.28206ISI: 000342763200042PubMedID: 24608912OAI: oai:DiVA.org:oru-56351DiVA: diva2:1081818
Note

Funding Agencies:

GlaxoSmithKline

Novartis

Pfizer

Available from: 2017-03-15 Created: 2017-03-15 Last updated: 2017-03-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jacobsson, Susanne
By organisation
Orebro University Hospital
In the same journal
Human Vaccines & Immunotherapeutics
Immunology in the medical areaMicrobiology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf